Published in Front Immunol on October 06, 2016
A Study of RO6895882 in Patients With Advanced and/or Metastatic Solid Tumors | NCT02004106
A Study of RO6958688 in Patients With Locally Advanced and/or Metastatic Solid Tumors | NCT02324257
A Study of LY3164530 in Participants With Cancer | NCT02221882
Structural basis of a novel heterodimeric Fc for bispecific antibody production. Oncotarget (2017) 0.75
A new approach for generating bispecific antibodies based on a common light chain format and the stable architecture of human immunoglobulin G1. J Biol Chem (2017) 0.75
Computational Design of a Specific Heavy Chain/κ Light Chain Interface for Expressing Fully IgG Bispecific Antibodies. Protein Sci (2017) 0.75
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science (2008) 5.30
Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science (2007) 4.52
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood (2008) 4.10
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science (2009) 3.87
IL-12 family cytokines: immunological playmakers. Nat Immunol (2012) 3.12
Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest (1999) 2.61
Simultaneous targeting of multiple disease mediators by a dual-variable-domain immunoglobulin. Nat Biotechnol (2007) 2.53
Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci Transl Med (2011) 2.51
'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng (1996) 2.44
An antagonist peptide-EPO receptor complex suggests that receptor dimerization is not sufficient for activation. Nat Struct Biol (1998) 2.24
Structure and function of immunoglobulins. J Allergy Clin Immunol (2010) 2.22
Dual targeting strategies with bispecific antibodies. MAbs (2012) 2.13
IgG subclasses and allotypes: from structure to effector functions. Front Immunol (2014) 1.95
An efficient route to human bispecific IgG. Nat Biotechnol (1998) 1.93
IgG4 breaking the rules. Immunology (2002) 1.93
Structural comparison of fucosylated and nonfucosylated Fc fragments of human immunoglobulin G1. J Mol Biol (2007) 1.89
Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc Natl Acad Sci U S A (2011) 1.85
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat Biotechnol (2014) 1.77
Alternative molecular formats and therapeutic applications for bispecific antibodies. Mol Immunol (2015) 1.76
Agonistic monoclonal antibodies against the Met receptor dissect the biological responses to HGF. J Cell Sci (1998) 1.75
Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat Biotechnol (2013) 1.71
Pulmonary delivery of an erythropoietin Fc fusion protein in non-human primates through an immunoglobulin transport pathway. Proc Natl Acad Sci U S A (2004) 1.69
Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med (2014) 1.63
Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J Biol Chem (2010) 1.60
Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J Immunol (1995) 1.53
Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A. N Engl J Med (2016) 1.52
A small bispecific antibody construct expressed as a functional single-chain molecule with high tumor cell cytotoxicity. Proc Natl Acad Sci U S A (1995) 1.46
Computationally Designed Bispecific Antibodies using Negative State Repertoires. Structure (2016) 1.45
Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med (2012) 1.44
Bispecific antibodies. Drug Discov Today (2015) 1.44
Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc Natl Acad Sci U S A (2013) 1.42
Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library. J Mol Biol (1997) 1.40
Targeting T cells to tumor cells using bispecific antibodies. Curr Opin Chem Biol (2013) 1.39
Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics. BioDrugs (2006) 1.37
SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng Des Sel (2010) 1.32
Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology. Curr Opin Biotechnol (2009) 1.31
Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J Mol Biol (2012) 1.30
Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies. MAbs (2012) 1.29
Bispecific human IgG by design. J Immunol Methods (2001) 1.28
Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A (2013) 1.20
T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy. J Exp Med (1996) 1.17
Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem (2010) 1.15
Building better monoclonal antibody-based therapeutics. Nat Rev Cancer (2015) 1.15
A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Nat Med (2012) 1.14
The structural basis of antibody-antigen recognition. Front Immunol (2013) 1.14
Clinical pharmacology of recombinant human follicle-stimulating hormone (FSH). I. Comparative pharmacokinetics with urinary human FSH. Fertil Steril (1994) 1.13
Soluble monomeric IgG1 Fc. J Biol Chem (2012) 1.06
Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2. Cancer Cell (2015) 1.04
Molecular properties of human IgG subclasses and their implications for designing therapeutic monoclonal antibodies against infectious diseases. Mol Immunol (2015) 1.03
Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity. PLoS One (2013) 1.03
A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs (2011) 1.02
Biodistribution of a bispecific single-chain diabody and its half-life extended derivatives. J Biol Chem (2009) 1.01
Delivery of an erythropoietin-Fc fusion protein by inhalation in humans through an immunoglobulin transport pathway. J Aerosol Med (2005) 1.01
Antibody-cytokine fusion proteins. Arch Biochem Biophys (2012) 0.98
Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design. MAbs (2013) 0.98
Oral and pulmonary delivery of FSH-Fc fusion proteins via neonatal Fc receptor-mediated transcytosis. Hum Reprod (2005) 0.97
Fc fusion as a platform technology: potential for modulating immunogenicity. Trends Biotechnol (2014) 0.96
A novel antibody engineering strategy for making monovalent bispecific heterodimeric IgG antibodies by electrostatic steering mechanism. J Biol Chem (2015) 0.95
Molecular characterization of novel trispecific ErbB-cMet-IGF1R antibodies and their antigen-binding properties. Protein Eng Des Sel (2012) 0.94
Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun (2015) 0.93
A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clin Cancer Res (2016) 0.93
The antibody-based delivery of interleukin-12 to the tumor neovasculature eradicates murine models of cancer in combination with paclitaxel. Clin Cancer Res (2012) 0.92
Bispecific antibodies and their applications. J Hematol Oncol (2015) 0.92
Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk. Cancer Res (2014) 0.91
Antigen specificity can be irrelevant to immunocytokine efficacy and biodistribution. Proc Natl Acad Sci U S A (2015) 0.91
Protein-protein recognition and the association of immunoglobulin constant domains. J Mol Biol (1990) 0.91
A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol Cancer Ther (2013) 0.90
Expression of soluble and functional human neonatal Fc receptor in Pichia pastoris. Protein Expr Purif (2009) 0.90
An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties. Int J Cancer (2006) 0.90
A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties. J Biol Chem (2014) 0.88
Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction. J Mol Biol (2014) 0.88
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters. BioDrugs (2015) 0.87
Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel (2011) 0.84
Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs. Mol Immunol (2013) 0.84
A Novel Bispecific Antibody Targeting EGFR and cMet Is Effective against EGFR Inhibitor-Resistant Lung Tumors. Cancer Res (2016) 0.84
Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7. J Biotechnol (2011) 0.84
Humanization of a phosphothreonine peptide-specific chicken antibody by combinatorial library optimization of the phosphoepitope-binding motif. Biochem Biophys Res Commun (2015) 0.83
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunol Rev (2016) 0.82
The use of CrossMAb technology for the generation of bi- and multispecific antibodies. MAbs (2016) 0.82
Protein engineering and the use of molecular modeling and simulation: the case of heterodimeric Fc engineering. Methods (2013) 0.81
Fab-based bispecific antibody formats with robust biophysical properties and biological activity. MAbs (2015) 0.81
Construction of a large synthetic human Fab antibody library on yeast cell surface by optimized yeast mating. J Microbiol Biotechnol (2014) 0.79
Immunocytokines for cancer treatment: past, present and future. Curr Opin Immunol (2016) 0.79
Antitumor immunity: easy as 1, 2, 3 with monoclonal bispecific trifunctional antibodies? Cancer Res (2013) 0.79
Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy. Leuk Lymphoma (2016) 0.78
Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation. Mol Immunol (2015) 0.78
Immunoglobulin Transporting Receptors Are Potential Targets for the Immunity Enhancement and Generation of Mammary Gland Bioreactor. Front Immunol (2016) 0.77
Immunoglobulin Fc-fused, neuropilin-1-specific peptide shows efficient tumor tissue penetration and inhibits tumor growth via anti-angiogenesis. J Control Release (2015) 0.77
Production of bispecific antibodies in "knobs-into-holes" using a cell-free expression system. MAbs (2015) 0.76
Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening. PLoS One (2015) 0.76